The size of the Global Checkpoint Inhibitors Market was valued at USD 12.9 billion in 2019 and is expected to reach USD 45.4 billion by 2024 with a CAGR of 28.68 % during the forecast period 2019 - 2024.
Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead an immune system attack on cancer cells. T-cells launch an attack when it detects infected or Cancerous. The immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack. Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells which lets T-Cells launch an attack on cancer cells.
Rising Prevalence of cancer globally, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the Checkpoint Inhibitors Market.
Some of the other prominent factors that drive the growth of the global checkpoint inhibitors market are the increase in funds, support from the government in developing new drugs and frequent rise in cancer. Precision in medicine will be a major driver for pharmaceuticals to deliver innovative medicines. There is an extreme force of competition in checkpoint inhibitors, which is driving the learning or developing skill and in-license agreements. This is also driven by research developments made by learning institutes and industry contributors. By affecting the cost of the nation, there is a need to address the day to day increase of cancer prevalence.
A comprehensive analysis of regions is to provide the current opportunities. It also offers a quantitative study to enable the stakeholders to make a massive amount in market opportunities.
The high cost that is involved in research and development is one of the major factors restraining from the global checkpoint inhibitors market. In addition, the lack of awareness and proper publicity for the use of these inhibitors, especially in the developing regions, are also acting as deterrents for the expansion of the global checkpoint inhibitors market.
Recent Developments
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 – 2024 |
|
Segments Analysed |
By Drug, Application, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
|
Companies Analysed |
Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma |
This research report on the Global Checkpoint Inhibitors Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.
Checkpoint Inhibitors Market Analysis - By Drug:
On the basis of drugs, the CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its market share to the PD-1 inhibitors segment during the forecast period as the majority of new treatments are based on PD-1 inhibitors.
Checkpoint Inhibitors Market Analysis - By Application:
Regional Analysis:
North America dominates the global checkpoint inhibitors market, owing to high clinics and also the availability of funds. But, APAC, i.e., Asia-Pacific is the fastest-growing region. In this region, international players collaborate with local companies. Asia-Pacific produces a great deal of profit for the key players, who are operating in the immune checkpoint inhibitors market, which is supported by its large population and their awareness about the immune therapy, etc.
Latin America and Middle East & Africa are also expected to produce a great deal of profit for the key players during the forecast period. Due to the development in healthcare, there will be a rise in demand for checkpoint inhibitors market in all parts of the world.
Key market participants leading the Global Checkpoint Inhibitors Market profiled in the report are:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Type
5.1.1 Introduction
5.1.2 PD-1 inhibitors
5.1.3 PD-L1 inhibitors
5.1.4 CTLA-4
5.1.5 Chimeric Antigen Receptor T-cell
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By Drug Type
5.1.8 Market Attractiveness Analysis, By Drug Type
5.1.9 Market Share Analysis, By Drug Type
5.2 Application
5.2.1 Introduction
5.2.2 Lung cancer
5.2.3 Renal cancer
5.2.4 Blood cancer
5.2.5 Bladder Cancer
5.2.6 Hodgkin lymphoma
5.2.7 Melanoma
5.2.8 Others
5.2.9 Y-o-Y Growth Analysis, By Application
5.2.10 Market Attractiveness Analysis, By Application
5.2.11 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Type
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Type
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Type
6.1.5.3 By Application
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Merck & Co., Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bristol-Myers Squibb
8.3 Roche
8.4 AstraZeneca
8.5 Ono Pharmaceutical Co., Ltd.
8.6 Juno Therapeutics
8.7 Novartis International AG
8.8 Kite Pharma
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
